Journal
CURRENT TOPICS IN MEDICINAL CHEMISTRY
Volume 16, Issue 4, Pages 415-426Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1568026615666150813145629
Keywords
Class I; Class II; Class III; HDAC; HDAC1; HDAC6; Selective histone deacetylase inhibitors
Categories
Funding
- National Natural Science Foundation [21172220, 21472191]
- Joint Fund of NSFC-Guangdong Province [U1401225]
Ask authors/readers for more resources
HDAC inhibitors (HDACIs), which can be used to kill cancer cells through inhibiting histone deacetylase activity or altering the structure of chromatin, have emerged as efficacious agents in the treatment of cancer. With SAHA, FK228, belinostat and panobinostat approved by the FDA, displaying satisfying activity in both haematological and solid tumors of various tissues, efforts to create selective HDACIs have been attracted attention over the past several years. Herein, we mainly review the progress of selective HDAC inhibitors including class-selective and isoform-selective HDAC inhibitors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available